1. Anti‐myelin antibodies play an important role in the susceptibility to develop proteolipid protein‐induced experimental autoimmune encephalomyelitis. (February 2014) Authors: Marín, N.; Eixarch, H.; Mansilla, M. J.; Rodríguez‐Martín, E.; Mecha, M.; Guaza, C.; Álvarez‐Cermeño, J. C.; Montalban, X.; Villar, L. M.; Espejo, C. Journal: Clinical and experimental immunology Issue: Volume 175:Number 2(2014:Feb.) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cellular immune responses in multiple sclerosis patients treated with interferon‐beta. (4th February 2013) Authors: Bustamante, M. F.; Rio, J.; Castro, Z.; Sánchez, A.; Montalban, X.; Comabella, M. Journal: Clinical and experimental immunology Issue: Volume 171:Number 3(2013:Mar.) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3‐like 1 and neurofilament light chain. (22nd June 2018) Authors: Quintana, E.; Coll, C.; Salavedra‐Pont, J.; Muñoz‐San Martín, M.; Robles‐Cedeño, R.; Tomàs‐Roig, J.; Buxó, M.; Matute‐Blanch, C.; Villar, L. M.; Montalban, X.; Comabella, M.; Perkal, H.; Gich, J.; Ramió‐Torrentà, L. Journal: European journal of neurology Issue: Volume 25:Number 9(2018) Page Start: 1189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. (19th January 2018) Authors: Montalban, X.; Gold, R.; Thompson, A. J.; Otero‐Romero, S.; Amato, M. P.; Chandraratna, D.; Clanet, M.; Comi, G.; Derfuss, T.; Fazekas, F.; Hartung, H. P.; Havrdova, E.; Hemmer, B.; Kappos, L.; Liblau, R.; Lubetzki, C.; Marcus, E.; Miller, D. H.; Olsson, T.; Pilling, S. Journal: European journal of neurology Issue: Volume 25:Number 2(2018) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Issue 8 (August 2019) Authors: Hauser, S.; Hartung, H.P.; Kappos, L.; Montalban, X.; Hughes, R.; Koendgen, H.; McNamara, J.; Pradhan, A.; Wormser, D.; Wolinsky, J.S. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease‐related disability. (28th July 2020) Authors: Vidal‐Jordana, A.; Pareto, D.; Cabello, S.; Alberich, M.; Rio, J.; Tintore, M.; Auger, C.; Montalban, X.; Rovira, A.; Sastre‐Garriga, J. Journal: European journal of neurology Issue: Volume 27:Number 11(2020) Page Start: 2225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Issue 8 (August 2019) Authors: Hauser, S.L.; Hartung, H.P.; Brochet, B.; Montalban, X.; Naismith, R.T.; Wolinsky, J.S.; Manfrini, M.; Garas, M.; Model, F.; Hubeaux, S.; Kappos, L. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Issue 8 (August 2019) Authors: Wolinsky, J.S.; Hartung, H.P.; Brochet, B.; Montalban, X.; Naismith, R.T.; Manfrini, M.; Garas, M.; Model, F.; Hubeaux, S.; Kappos, L.; Hauser, S.L. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon‐β treatment. Issue 10 (22nd May 2013) Authors: Malhotra, S.; Morcillo‐Suárez, C.; Nurtdinov, R.; Rio, J.; Sarro, E.; Moreno, M.; Castilló, J.; Navarro, A.; Montalban, X.; Comabella, M. Journal: European journal of neurology Issue: Volume 20:Issue 10(2013:Oct.) Page Start: 1390 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗